Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19643323 | 0.85 | IDO1 (0.44) | IDO1CA1CA2SMN1; SMN2 | |
| SCHEMBL13885072 | 0.83 | MEP1B (0.46) | CNR2PTPN7DUSP3MMP13 | |
| SCHEMBL52399 | 0.82 | MMP13 (0.44) | PTPN7DUSP3IDO1FPR3FPR2 | |
| SCHEMBL149307 | 0.81 | HDAC1 (0.50) | PTPN1MMP13HDAC6 | |
| SCHEMBL14966524 | 0.80 | NR1H4 (0.48) | CNR2MMP13 | |
| SCHEMBL8187730 | 0.80 | ALDH1A1 (0.52) | SMN1; SMN2HDAC6 | |
| SCHEMBL20289377 | 0.78 | TGM2 (0.54) | CA1CA2SMN1; SMN2HDAC6 | |
| SCHEMBL51488 | 0.77 | GRM2 (0.47) | IDO1FPR3FPR2CA1CA2 | |
| SCHEMBL30457513 | 0.77 | GRM2 (0.47) | IDO1FPR3FPR2CA1CA2 | |
| SCHEMBL232868 | 0.76 | MTOR (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516428-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| WO-2011087652-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011087652-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | CNR2 326/4885PTPN7 3821/4885DUSP3 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.